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Abstract
Glucocorticoid hormones (GCs) are used to treat a variety of diseases because of their
potent anti-inflammatory effect and their ability to induce apoptosis in lymphoid malignan-
cies through the glucocorticoid receptor (GR). Despite ongoing research, high glucocorticoid
efficacy and widespread usage in medicine, resistance, disease relapse and toxicity remain
factors that need addressing. Understanding the mechanisms of glucocorticoid signalling
and how resistance may arise is highly important towards improving therapy. To gain insight
into this we undertook a systems biology approach, aiming to generate a Boolean model of
the glucocorticoid receptor protein interaction network that encapsulates functional relation-
ships between the GR, its target genes or genes that target GR, and the interactions
between the genes that interact with the GR. This model named GEB052 consists of 52
nodes representing genes or proteins, the model input (GC) and model outputs (cell death
and inflammation), connected by 241 logical interactions of activation or inhibition. 323
changes in the relationships between model constituents following in silico knockouts were
uncovered, and steady-state analysis followed by cell-based microarray genome-wide
model validation led to an average of 57% correct predictions, which was taken further by
assessment of model predictions against patient microarray data. Lastly, semi-quantitative
model analysis via microarray data superimposed onto the model with a score flow algo-
rithm has also been performed, which demonstrated significantly higher correct prediction
ratios (average of 80%), and the model has been assessed as a predictive clinical tool using
published patient microarray data. In summary we present an in silico simulation of the glu-
cocorticoid receptor interaction network, linked to downstream biological processes that can
be analysed to uncover relationships between GR and its interactants. Ultimately the model
provides a platform for future development both by directing laboratory research and allow-
ing for incorporation of further components, encapsulating more interactions/genes involved
in glucocorticoid receptor signalling.
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Author summary
Here we present modelling of the glucocorticoid receptor (GR) signalling network. The
GR is the effector for a class of drugs known as corticosteroids, which are widely used in
medicine for their anti-inflammatory effects and ability to induce apoptosis in leukaemic
cells. However, side effects, treatment-related toxicity and glucocorticoid resistance
remain and therefore increased understanding of the glucocorticoid receptor mechanism
of action may improve therapeutic outcomes. The GEB052 model presented herein has
been used to generate predictions for how the network is altered between glucocorticoid-
sensitive and glucocorticoid-resistant scenarios, and these predictions have been verified
using published gene expression data from established cell lines (for both qualitative and
semi-quantitative analysis). The model has also been preliminarily assessed as a predictive
clinical tool by correlating model predictions with clinical outcomes of thirteen leukaemia
patients. Thus, the GEB052 model demonstrates successful modelling to understand GR
function. GEB052 provides accurate predictions and has indicated potential routes
through which glucocorticoid resistance may arise. The work presented herein thus dem-
onstrates a proof-of-principle of this modelling approach to furthering GR research, and
provides insight into potential mechanisms of corticosteroids resistance.
Introduction
Glucocorticoids (GCs) steroid hormones released from the adrenal cortex as part of the stress
response play an important role in a variety of bodily processes such as inflammation, immu-
nity, and numerous metabolic processes [1–3]. Their varied effects allow for their clinical
application in numerous diseases, particularly for their potent anti-inflammatory and immu-
nosuppressive effects to treat diseases such as arthritis [4, 5]. GCs are also prescribed for the
treatment of lymphoid cancers, as they selectively induce cell death in leukocytes [6–8],
highlighting the tissue specificity of their action and the need for further research into GC
signalling.
GCs exert their effects through the glucocorticoid receptor (GR) which is an intracellular
cytoplasmic receptor which, in the absence of a ligand, is part of a complex with chaperones
such as heat-shock protein 90 [9]. Following ligand binding, GR dissociates from this complex
and translocates to the nucleus where it regulates the expression of its target genes as an active
transcription factor [10, 11]. Numerous factors control GR activity, including phosphorylation
status [12], targeting to protein degradation pathways [13] and interaction with cofactors [14].
Clinically, synthetic GCs such as dexamethasone are used due to their higher potency and
stability. Whilst GCs have achieved significant therapeutic outcomes, resistance to treatment
and side-effects both remain an issue. Defective GR expression, Bcl-2 overexpression, and
other aberrant signalling may contribute to glucocorticoid resistance [6, 15, 16]. Increased
knowledge into the details of GR signalling may allow for the development of novel therapeu-
tics and identification of resistance factors. Although high-throughput methodologies have
provided insight into GR signalling [6], there remains a need to properly integrate large data-
sets in a cohesive manner.
Systems biology aims to accurately represent biological phenomena by constructing inte-
grative models of molecular components and their interactions. Some models are quantita-
tively precise and require measurement of biological kinetic data, though they are often of a
smaller scale, aiming to precisely model a particular subset of interactions. This approach has
been applied to glucocorticoid research in numerous ways, such as the development of models
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of GR/c-Jun/Erg (Ets-related gene) crosstalk [17]. The models of GR/c-Jun/Erg confirmed
known interaction phenomena but also identified Erg as a putative marker for glucocorticoid
resistance [17]. Although such models provide useful insight, they are both time-consuming
and resource-expensive to create due to the required biological data. Boolean modelling on the
contrary allows for the generation of large-scale models that provide a qualitative overview of
the behaviour of an entire network [18, 19]. In these cases, interactions and molecular levels
are simplified to ON or OFF binary values, removing the need to know exact rate and kinetic
equations thus reducing computational demand [20].
We have previously demonstrated that Boolean modelling may be successfully applied to
cancer research through generating the PKT206 model of the p53 interactome [18] which has
revealed novel mechanisms of p53 signalling and how this may be disrupted following loss of
p53 function. Correct prediction rates reached 71% for the model, signifying the strength of
this approach [18]. An expanded p53 interactome was later developed to more accurately
model the signalling phenomena [19].
To overcome the qualitative nature of the Boolean modelling approach algorithms utilising
microarray and/or ChIP-seq data have been developed such as the signal transduction score
flow algorithm (STSFA) which analyses Boolean models in a semi-quantitative manner [21].
This algorithm has been applied to the original PKT206 model [22], which demonstrated
improved predictive power over the original model analysis. Thus, application of this or simi-
lar algorithms represents a way to improve model accuracy through its semi-quantitative
nature.
The aim of this research was to develop a Boolean model for the GR interaction network
similar to the p53 interactomes [18, 19]. The model (GEB052: Glucocorticoid receptor model
by Emyr Bakker, consisting of 52 nodes) contains 241 interactions. Nodes represent genes/
proteins or inputs (glucocorticoid)/outputs (cell death and inflammation). CellNetAnalyzer
[23] has been used for in silico analysis. Boolean model performance was assessed via compari-
son to microarray data [18] which demonstrated up to 60.4% of predictions depending on
microarray data used for validation (average 57%) as correct, whilst STSFA analysis indicated
a correct prediction rate of 80.1%. Using microarray data from thirteen leukaemia patients the
model has been assessed as a predictive clinical tool. This report demonstrates the applicability
of this modelling approach to nuclear receptor research, with the overarching aim being to
eventually create models in a tissue-type, disease-specific and patient-centred manner.
Results
GEB052 network generation
The GEB052 model was built via a similar workflow to the PKT206 model [18] (Fig 1).
STRING (Search Tool for the Retrieval of Interacting Genes/Proteins) is a database that pro-
vides information on functional associations between proteins, and thus this database repre-
sented a starting point for the interactions to be included within the model [24, 25]. Nodes
within this model represent genes (or their associated proteins) and inputs/outputs such as the
glucocorticoid and cell death and inflammation respectively. Model edges represent activation
or inhibition relationships between model constituents.
To ensure consistency and cohesiveness of the model for the primary layer (proteins inter-
acting with the GR), proteins interacting in a highly indirect manner (i.e. through multiple
steps and proteins) were excluded during curation. The curation evidence used for cofactors
would indicate either the stimulatory or inhibitory effect of that cofactor on the GR, or a report
demonstrating that the cofactor in question was a GR coactivator or corepressor. For the cura-
tion of the second layer (interactions between the proteins within the primary layer) the
Boolean modelling of the glucocorticoid receptor
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“intermediary rule” was applied. This rule covered cases for which literature curation indicated
that despite STRING listing a direct link between Protein 1 and Protein 2 (both of which inter-
act with the GR individually), this regulation actually occurred through an intermediary pro-
tein (i.e. Protein 1 -> Intermediary Protein -> Protein 2). In these cases, if the intermediary
protein was present within the primary layer then the reactions would be listed as proceeding
through the intermediary protein (i.e. Protein 1 -> Intermediary Protein -> Protein 2), pro-
vided no additional evidence of a direct relationship of Protein 1 -> Protein 2 was observed.
In cases where the intermediary protein did not exist within the primary layer, the reaction
instead was put as a direct Protein 1 -> Protein 2 to reduce redundancy.
In numerous cases, multiple proteins were combined as one node within the model. This
was due to either the proteins forming a heterodimer or proteins from the same family being
grouped together. These nodes and their constituents can be seen in the S1 Text file.
Following completion of the second layer, the model was connected to cell death and inflam-
mation as two outputs through Gene Ontology. The full curation tables for the model (detailing
the mode of interaction and at least one PubMed ID linking to a paper verifying the interaction)
for the primary layer, second layer, and link to outputs can be seen in the S1 Text file.
GEB052 model structure
The GEB052 model (Fig 2) consists of 52 nodes (proteins, inputs, outputs) connected by 241
logical interactions of activation or inhibition. Although the visualisation shown above is
Fig 1. Flow chart demonstrating the workflow of GEB052 model construction and analysis. Database files were downloaded from the STRING
website and interactions for proteins of interest were extracted. Extensive manual curation of predicted interactions was performed via literature searching,
and the model was linked to biological outputs (cell death and inflammation) through manual curation of Gene Ontology records. CellNetAnalyzer (CNA)
and the Signal Transduction Score Flow Algorithm (STSFA) were used for model analysis, with model predictions being verified via microarray data. The
dashed line from Model Validation to The GEB052 Model represents validation and potential model refinement through assessment of model predictions.
https://doi.org/10.1371/journal.pcbi.1005825.g001
Boolean modelling of the glucocorticoid receptor
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useful for providing an overview, it can be difficult to follow individual reactions in this
detailed overview. As a complement to the full visualisation shown above, an interaction
matrix (generated in CNA) is shown in Fig 3.
Feedback loops within biological networks are essential to maintain network integrity [18].
The GEB052 model contained 64 two step (i.e. Protein 1 -> Protein 2 -> Protein 1) loops, 26
of which (40.6%) involved the GR. This thus highlights the obvious centrality and importance
of the GR within the network. Only two-step feedback loops are considered for examination as
Fig 2. The GEB052 model. Nodes are represented by small blue circles, with the exception of the Input Node (GC) which is a green circle. The
red circle represents the central node (the GR). Cell death and inflammation, the two model outputs, are shown in blue squares. Inhibitory edges
are shown as red closed arrows whilst activation edges are shown as green open arrows.
https://doi.org/10.1371/journal.pcbi.1005825.g002
Boolean modelling of the glucocorticoid receptor
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feedback loops may otherwise consist of numerous steps which would complicate analysis
[18].
In addition to feedback loop assessment, the degree (node connectivity) distribution was
assessed (Fig 4). Excluding cell death and inflammation, six nodes demonstrated a very high
level of connectivity (twenty or more edges). On the far right of Fig 4 is the GR, with a degree
of 83. In addition to the GR, other nodes showing a very high degree include: AP-1 (36 edges);
CREBBP/EP300 (20 edges); IL6 (21 edges); STAT3 (20 edges) and TP53 (22 edges). Other
nodes exhibiting a high degree (ten or more edges) include: CREB1 (12 edges); HDAC1 (14
interactions); HSP90 (11 edges); IL10 (15 edges); NFKB (16 edges); SMAD3 (13 edges) and
SUMO (10 edges). Other nodes (n = 37) exhibited a lower degree, possessing less than ten
edges. Table 1 summarises the degree range observed within the model.
Understanding the node connectivity within the model was crucial to the choice of which
nodes would be selected for in silico knockout analysis, as previous studies have focussed on in
silico knockouts for only the most highly connected nodes [18, 19].
Dependency and in silico knockout analysis of GEB052 model
CNA is capable of generating a dependency matrix which, by taking into account all of the sig-
nalling pathways present within the model, is able to determine the overall relationships from
one node to another. Six types of dependencies are available: no effect; ambivalent (stimulatory
and inhibitory influence); weak inhibitor; weak activator; strong inhibitor and strong activator.
Fig 5 shows the visualised dependency matrix for the full GEB052 model. It is apparent from
examination of Fig 5 that the majority of dependencies are ambivalent factors. This observation
Fig 3. Interaction matrix for GEB052 model. Figure adapted from the CNA-generated interaction matrix. The right-hand y-axis shows the number of
reactions that each node is involved in, whilst the left-hand y axis shows the nodes present within the model. For the right-hand axis, numbers in brackets
are equal to the number of nodes it activates, the number of nodes it inhibits, and the number of nodes it is regulated by. All model nodes for all model edges
are assigned a value in the interaction matrix. Black is equivalent to no participation, whilst blue means the node is affected (i.e. regulated) by the interaction.
Red means the node has an inhibition input whilst green means the node has a stimulatory input.
https://doi.org/10.1371/journal.pcbi.1005825.g003
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correlates with the large number of feedback loops, as the highly integrated signalling within the
model can lead to multiple signalling paths between model nodes, both positive and negative.
As ambivalent dependencies are those most likely to change following in silico knockouts, the
high number of ambivalent dependencies represents a good starting point for downstream
analysis.
In total, 2704 (5252) dependencies were observed within the GEB052 model: 896 of these
were of no effect; 1710 were ambivalent; 33 were weak inhibitors; 63 were weak activators; 2
were strong activators and there were no strong inhibitors. To characterise how relationships
are altered after perturbation to the model (mimicking potential mutations in vivo), each of
the highly connected nodes (10 interactions, excepting model outputs) was deleted from the
model and a dependency matrix generated, with the results shown in Table 2.
For each knockout above, a total of 2601 (5151) dependencies was observed and as
expected due its centrality within the model, the removal of the GR had the most significant
effects on the dependencies (Fig 6). The majority of dependency alterations were from
Fig 4. Node connectivity of GEB052 model. The number of edges interacting with the node is shown on the y-axis whilst the number of nodes
with that degree of connectivity is shown on the x-axis.
https://doi.org/10.1371/journal.pcbi.1005825.g004
Table 1. Node connectivity of GEB052 model.
Node Degree Range Number of Nodes Percentage of Total Nodes
Connectivity > 80 1 1.9%
10 Connectivity 80 14 26.9%
0 < Connectivity < 10 37 71.2%
https://doi.org/10.1371/journal.pcbi.1005825.t001
Boolean modelling of the glucocorticoid receptor
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ambivalent factors to no effect, which is consistent with the high connectivity of the GR result-
ing in many nodes signalling through it to affect others. Thus, removal of this intermediary
node results in a loss of signalling between model constituents.
Fig 5. Dependency matrix for GEB052 model. Dependencies show the effect of the node on the y-axis on the node on the x-axis.
https://doi.org/10.1371/journal.pcbi.1005825.g005
Table 2. Dependency matrix alterations following in silico knockout analysis.
Scenario Number of Each Dependency
No Effect Ambivalent Weak
Inhibitor
Weak
Activator
Strong
Inhibitor
Strong
Activator
Total
Full Model 896 1710 33 63 0 2 2704
AP-1 KO 877 1581 66 75 0 2 2601
CREB1 KO 877 1626 33 63 0 2 2601
CREBBP/
EP300 KO
877 1576 61 85 0 2 2601
GR KO 1602 955 5 35 1 3 2601
HDAC1 KO 953 1541 36 65 0 6 2601
HSP90 KO 993 1481 53 68 0 6 2601
IL6 KO 877 1607 43 72 0 2 2601
IL10 KO 877 1626 33 63 0 2 2601
NFKB KO 877 1626 33 63 0 2 2601
SMAD3 KO 877 1626 33 63 0 2 2601
STAT3 KO 877 1574 63 85 0 2 2601
SUMO KO 917 1589 33 60 0 2 2601
TP53 KO 917 1579 36 67 0 2 2601
https://doi.org/10.1371/journal.pcbi.1005825.t002
Boolean modelling of the glucocorticoid receptor
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In addition to the changes from ambivalent to no effect, numerous changes to and from
other dependencies were observed across the numerous knockout scenarios. Across all knock-
out scenarios for the GEB052 model a total of 1249 dependency alterations was observed,
which is reflective of the significant number of relationship changes that occur when network
elements are lost. Even if changes from ambivalent factors to no effects are not considered (as
there is no net change in positive or negative regulation) 323 predictions of dependency alter-
ations (to or from activators or inhibitors) were seen. Although these all may exert physiologi-
cal effects when translated from in silico to in vivo, it is anticipated that strong activators or
strong inhibitors are the dependencies most likely to show an effect. Therefore there is a neces-
sary focus on changes to or from strong inhibitors to strong activators, as has been performed
previously for interactome modelling [19, 22].
For example, removal of the GR (which mimics GR mutation in vivo), resulted in the emer-
gence of one strong inhibitor and one additional strong activator when compared to the wild
type model (Table 2). In the unperturbed model DAP3 was ambivalent towards cell death
whereas in the absence of the GR it became strong activator. In addition, STAT5B in the wild
type model was ambivalent towards cell death whereas removal of the GR led to the dependency
Fig 6. Dependency alteration distribution following an in silico GR knockout. This figure shows the alteration of
dependencies following the removal of the GR node from the GEB052 model. Ambivalent dependencies are represented
by a yellow circle, whilst weak activators and inhibitors are represented by a light green and pink circle respectively. The
dark green circle represents strong activators, whilst the dark red circle represents strong inhibitors. No effect
dependencies are represented by the dark grey circle.
https://doi.org/10.1371/journal.pcbi.1005825.g006
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changing to strong inhibition. These predictions if confirmed by literature searches and labora-
tory-based experiments may have important clinical implications.
To assess the accuracy of the model published literature was surveyed to investigate whether
the model predictions in dependency alterations have been previously observed in experimen-
tal research. The predictions that could not be verified by literature searching, were marked as
a “Potentially Novel Prediction” [18] and the results are detailed in Table 3.
Literature validation requires that the KO node, Node A and Node B are all mentioned; for
instance, for row four of the above table, the paper would have to mention HDAC1 silencing
or inhibition, which leads to DAXX activating SUMO. Otherwise, effects could be non-specific
and not wholly consistent with model prediction. During the initial literature validation papers
mentioning all three nodes could not be found.
However, some preliminary evidence has been gathered. The model predicted that in the
absence of HSP90, PRKDC would be strongly activated by NCOA6 and by itself (likely via feed-
back loops). Corroborating this to some extent is one report which investigated the relationship
between HSP90 and PRKDC (catalytic subunit of DNA-PK) and found that the use of the HSP90
inhibitor geldanamycin markedly enhanced TRAIL-induced DNA-PK [26]. However, this result
was complicated as the same paper also showed that DNA-PK is a client of HSP90, which was
required for full DNA-PK activation [26]. Thus, although the effector node (i.e. Node A) is not
mentioned, it is promising that the overall outcome may correlate with model prediction.
Similar to the above, the model predicted that SUMO expression would be significantly
higher following the loss of HDAC1. It has been shown that HDAC inhibition increases
sumoylation in general, however the effect in one instance was mediated primarily through
HDAC2 [27]. In addition, it has been demonstrated that HDAC1 inhibits sumoylation of a tar-
get protein therefore loss of HDAC1 would increase its sumoylation and thus the abundance
of SUMO protein [28]. Again, this is consistent with model predictions, however the effector
Node A (in this case DAXX or SUMO) has not been mentioned in this report.
Some model predictions were incorrect. The model predicted that loss of HDAC1 would lead to
increased expression of DAXX; however, research has shown the opposite, with HDAC inhibitors
leading to a decreased expression of DAXX [29]. But again, this paper does not specifically mention
DAXX or SUMO as the effector node, so it is only a preliminary assessment of model accuracy.
Genome-wide model analysis
Although analysis of individual relationships via dependency matrices may provide insight
into altered signalling, logical steady state analysis (LSSA) assesses the entirety of the model
Table 3. Potentially novel predictions from dependency alterations.
Node
Deleted
Node A Node B Wild-Type
Dependency
KO Dependency Verification
(PubMed ID)
Consistent with
Model Prediction?
GR DAP3 CELL-DEATH Ambivalent Strong Activator N/A Potentially Novel Prediction
GR STAT5B CELL-DEATH Ambivalent Strong Inhibitor N/A Potentially Novel Prediction
HDAC1 DAXX DAXX Ambivalent Strong Activator N/A Potentially Novel Prediction
HDAC1 DAXX SUMO Ambivalent Strong Activator N/A Potentially Novel Prediction
HDAC1 SUMO SUMO Ambivalent Strong Activator N/A Potentially Novel Prediction
HDAC1 SUMO DAXX Weak Activator Strong Activator N/A Potentially Novel Prediction
HSP90 PRKDC NCOA6 Weak Activator Strong Activator N/A Potentially Novel Prediction
HSP90 NCOA6 NCOA6 Ambivalent Strong Activator N/A Potentially Novel Prediction
HSP90 NCOA6 PRKDC Ambivalent Strong Activator N/A Potentially Novel Prediction
HSP90 PRKDC PRKDC Ambivalent Strong Activator N/A Potentially Novel Prediction
https://doi.org/10.1371/journal.pcbi.1005825.t003
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under different scenarios. The basal state for all model nodes is undetermined (NaN). Given a
set of input values (i.e. GC = 1 for a glucocorticoid-sensitive simulation, or GC = 1, GR = 0 for
a glucocorticoid-resistant simulation) LSSA will proceed to calculate the state (1/ON, NaN/
undetermined or 0/OFF) of every downstream node within the model. Lastly, two LSSA sce-
narios may be compared to generate an Emod value for each node which predicts the overall
state change of the node between the two scenarios (1 = upregulated, 0 = no change, -1 = down-
regulated). Fig 7 provides a visual representation of the LSSA results for both the glucocorti-
coid-sensitive and glucocorticoid-resistant simulations, whilst Table 4 below summarises the
LSSA results as well as the Emod value for each node.
More determined (ON or OFF) nodes were seen in the glucocorticoid-resistant simulation,
however this is balanced by the fact that a significantly higher number of nodes (23.1%) were
OFF in the glucocorticoid-resistant simulation, which may reflect a loss of overall functionality
within the network. The Emod values (upregulated, no change, or downregulated) for nodes are
summarised in Table 5.
Model predictions may be verified by literature searching in terms of experimental identifi-
cation of upregulation or downregulation between glucocorticoid-sensitive and glucocorticoid-
resistant cells. For instance, it has been shown that GLUL is downregulated in glucocorticoid-
resistant cells [30]. However, a more practical approach to validating model LSSA predictions is
the use of microarray data, detailed below.
Microarray data from glucocorticoid-sensitive and glucocorticoid-resistant cells were
obtained from the Gene Expression Omnibus database and six comparisons were per-
formed (as detailed in the Methods). The Emod values obtained above were compared to Eexp
values created via comparison of a glucocorticoid-sensitive and glucocorticoid-resistant
microarray. Comparison of these values gives the number of correct, small error and large
Fig 7. Visualisation of LSSA results from glucocorticoid-sensitive (A) and glucocorticoid-resistant (B) simulations. Nodes are coloured based on
LSSA results: green indicates the node’s LSSA result was 1; orange indicates the node’s LSSA result was NaN and red indicates the node’s LSSA result
was 0.
https://doi.org/10.1371/journal.pcbi.1005825.g007
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Table 4. LSSA results for glucocorticoid-sensitive and glucocorticoid-resistant simulations.
Node GC-Sensitive (GC = 1) Simulation GC-Resistant (GC = 1, GR = 0) Simulation Emod
14-3-3 1 1 0
ABCA1 1 1 0
AFP 1 0 -1
AP-1 1 1 0
ARHGAP35 1 0 -1
BAG1 NaN NaN 0
CD2 1 1 0
CD40LG 1 0 -1
CELL-DEATH 1 1 0
CREB1 1 1 0
CREBBP/EP300 1 1 0
CRH 1 1 0
DAP3 NaN NaN 0
DAXX NaN 1 1
FSCN1 1 1 0
GC 1 1 0
GLUL 1 0 -1
GR 1 0 -1
HDAC1 NaN 1 1
HDAC6 1 1 0
HSP90 1 1 0
IL10 1 1 0
IL6 1 1 0
INFLAMMATION 1 1 0
LIF 1 1 0
MED1 1 0 -1
NCOA1 1 1 0
NCOA2 1 1 0
NCOA3 1 1 0
NCOA6 1 1 0
NCOR1 NaN NaN 0
NCOR2 NaN NaN 0
NFKB 1 1 0
NR1I3 1 0 -1
NR2F2 1 0 -1
NRIP1 NaN NaN 0
PKA 1 1 0
POU2F1 1 1 0
POU2F2 1 1 0
PRKDC 1 1 0
PTGES3 1 1 0
SCAP 1 0 -1
SGK1 1 1 0
SMAD3 1 1 0
SMARCA4 NaN NaN 0
STAT3 1 1 0
STAT5B 1 0 -1
(Continued )
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error predictions within the model. The S1 Text file contains tables that show the Emod and
Eexp values in addition to their comparison for each microarray validation performed.
Table 6 below summarises the overall number of correct/small error/large error predictions
across all comparisons.
As shown above, the GEB052 model generated accurate predictions across all scenarios
(ranging from 54.2% to 60.4%, with an average of 56.6%). Given there are three possible out-
comes (correct, small error and large error) a random model would achieve an expected cor-
rect prediction rate of 33.3%. The correct predictions from the six comparisons when
compared to what a random model would achieve leads to a p-value <0.01, providing further
evidence of the predictive capacity and potential of the GEB052 model.
Preliminary clinical validation of the GEB052 model based on LSSA data
In addition to the cell-based microarray data described above, the GEB052 model has been
assessed as a predictive clinical tool (based on LSSA results) using microarray data from thir-
teen leukaemia patients (see the Methods section). The output of this result is shown in Fig 8,
and the model’s LSSA results perform less well for analysis of individual patient data as an
average correct prediction rate of 42% was observed, with 55% small error and 3% large error.
Thus, although 55% of predictions were small error, the fact that large errors are still less than
5% is a promising indicator of the potential of the model. The fixed-state nature of LSSA (hav-
ing only three discrete values) is a limitation on the analytical output which may partially
explain this outcome, and thus a more quantitative analysis was taken next.
Semi-quantitative model analysis via application of the signal
transduction score flow algorithm
The GEB052 model has also undergone analysis using a semi-quantitative signal transduction
score flow algorithm (STSFA) that superimposes ChIP-seq and/or microarray data onto a
Table 4. (Continued)
Node GC-Sensitive (GC = 1) Simulation GC-Resistant (GC = 1, GR = 0) Simulation Emod
SUMO NaN 1 1
TP53 1 1 0
TSC22D3 1 0 -1
TSG101 NaN NaN 0
UBC 1 0 -1
% ON 80.8 63.5
% OFF 0 23.1
% Determined 80.8 86.6
% Undetermined 19.2 13.4
https://doi.org/10.1371/journal.pcbi.1005825.t004
Table 5. Node state comparison from glucocorticoid-sensitive to glucocorticoid-resistant simulations. Upregulated and downregulated refer to the
fact that the node is more or less active in the glucocorticoid-resistant simulation than in the glucocorticoid-sensitive simulation.
Upregulated (3) Unchanged (37) Downregulated (12)
DAXX, HDAC1,
SUMO
14-3-3, ABCA1, AP-1, BAG1, CREBBP/EP300, CD2, CELL-DEATH, CREB1,
CRH, DAP3, FSCN1, GC, HDAC6, HSP90, IL10, IL6, INFLAMMATION, LIF,
NCOA1, NCOA2, NCOA3, NCOA6, NCOR1, NCOR2, NFKB, NRIP1,
PTGES3, TP53, PKA, POU2F1, POU2F2, PRKDC, SGK1, SMAD3,
SMARCA4, STAT3, TSG101
AFP, NR1I3, CD40LG, GLUL, GR, ARHGAP35,
MED1, NR2F2, SCAP, STAT5B, TSC22D3, UBC
https://doi.org/10.1371/journal.pcbi.1005825.t005
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model to analyse the network with numerical data. The same comparisons for genome-wide
validation was again utilised here (see Methods). The S1 Text file contains tables that show the
calculation and output for each individual STSFA analysis and a summary is provided in
Table 7.
As shown above in Table 7, STSFA analysis achieved significantly higher correct prediction
rates than for discrete LSSA predictions (compare to Table 6). An average of 80.1% correct
predictions was observed, with an average of 18.9% small error and 1.0% large error (and three
out of six simulations exhibiting no large errors). The correct prediction rates for LSSA against
STSFA have been graphed and compared via an unpaired t-test (Fig 9), which shows the
enhanced predictive power that the semi-quantitative STSFA analysis offers. Due to this,
Table 6. Summary of prediction rates across all LSSA microarray validations.
Comparison Correct (%) Small Error (%) Large Error (%) P-Value of Correct Predictions
1 58.3 41.7 0.0 0.00022
2 54.2 43.8 2.1 0.00144
3 60.4 37.5 2.1 0.0000758621
4 58.3 39.6 2.1 0.00022
5 54.2 41.7 4.2 0.00144
6 54.2 45.8 0.0 0.00144
AVERAGE 56.6 41.7 1.8 0.000679172
https://doi.org/10.1371/journal.pcbi.1005825.t006
Fig 8. Clinical validation of GEB052 model via comparison of LSSA data to patient-based microarrays. The “Patient Number” on the x-axis
refers to the patient number used in the original study [31] that these patients were taken from. An asterisk (*) indicates that the p-value of correct
predictions for that patient was statistically significant at p<0.05.
https://doi.org/10.1371/journal.pcbi.1005825.g008
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assessment of the clinical potential of the GEB052 model with STSFA analysis was performed,
as detailed below.
Clinical predictive power of the GEB052 model under STSFA analysis
Using microarray data from thirteen leukaemia patients (see Methods), the GEB052 model
was analysed with the STSFA and the relative activation/inhibition of cell death was calculated
for each patient. Patients were divided into two groups (twelve patients alive at risk assessment
or one deceased at risk assessment) and the average +/- SEM (Fig 10). GEB052 model predic-
tions indicated that the patient who died before risk assessment would have cell death more
negatively regulated than those who were alive at risk assessment. Given that glucocorticoids
Table 7. Prediction rates for the GEB052 model under STSFA analysis.
Comparison Correct (%) Small Error (%) Large Error (%) P-Value of Correct Predictions
1 82.6 17.4 0.0 7.53687×10−12
2 83.0 17.0 0.0 3.02763×10−12
3 87.2 12.8 0.0 2.58456×10−14
4 72.3 25.5 2.1 4.33425×10−8
5 74.5 23.4 2.1 8.04931×10−9
6 80.9 17.0 2.1 2.62395×10−11
AVERAGE 80.1 18.9 1.0 8.57144×10−9
https://doi.org/10.1371/journal.pcbi.1005825.t007
Fig 9. Correct predictions of LSSA against STSFA. Data represents the average correct prediction percentages +/- SEM. An asterisk (*) indicates
p<0.05 as assessed by an unpaired t-test.
https://doi.org/10.1371/journal.pcbi.1005825.g009
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are a chemotherapeutic drug for leukaemia, the cell death node in the model translates to
death of the cancer cells in vivo. Thus, the model predicted that the patient who died before
risk assessment would have cell death more negatively regulated; meaning that more cancer
cells survive, in turn suggesting a worse prognosis. Thus, these preliminary model predictions
correlate with clinical outcomes for the patients.
Discussion
The widespread therapeutic use of glucocorticoids for many different diseases leads to a need
to identify causes of therapy failure and glucocorticoid resistance. Systems biology offers the
possibility of integrating the detailed knowledge of GR signalling to generate models that can
be used to gain insight into how the network functions following a loss of GR function.
Computational research methodologies have been previously applied to GR research using
approaches such as virtual ligand screening [32], development of models to quantitatively
model specific signalling events [17] or the creation of models that aim to simulate glucocorti-
coid receptor control of both directly-regulated and indirectly-regulated genes [33]. Each of
these approaches have provided insight to GR signalling, however to date a Boolean interac-
tome model of the glucocorticoid receptor has not been developed. To generate the GEB052
model, the STRING database was to provide a basis for the interactions to be included. Follow-
ing the generation of all the model links between the proteins interacting with the GR, model
Fig 10. Clinical validation of the GEB052 model under STSFA analysis. The x-axis shows patient groups (Deceased at Risk Assessment, n = 1,
Alive at Risk Assessment, n = 12) and the average for each group of the total edge weights targeting cell death +/- SEM are shown on the y-axis. Patient
data taken from Schmidt and colleagues [31]and the GEO database.
https://doi.org/10.1371/journal.pcbi.1005825.g010
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outputs in the form of cell death and inflammation were added via Gene Ontology and manual
curation.
Interactome modelling has previously been applied to cancer research, such as the develop-
ment of the original PKT206 p53 interactome and the later expanded PMH260 interactome
[18, 19]. These models, in addition to the application of the STSFA to the PKT206 model [22]
all showed good predictive ratios and thus a similar approach was undertaken here to model
GR signalling.
The GEB052 model consists of 52 nodes connected by 241 logical interactions, and has 64
two-step feedback loops within the model. Comparatively, the PKT206 model had only 30
two-step feedback loops, whilst the expanded PMH260 model had only 34 feedback loops [18,
19]. The identification of 64 two-step feedback loops within the GEB052 model is particularly
interesting as the GEB052 model is significantly smaller than PKT206 or PMH260, containing
only 52 nodes compared to 206 or 260. Thus, despite the model being significantly smaller the
network appears to be much more integrated and interconnected, which may explain the fact
that the majority of nodes were unchanged between the sensitive and resistant LSSA simula-
tion results, as well as potentially explaining the fewer number of changes to strong activators
or inhibitors following dependency matrix generation in KO scenarios; the PKT206 model
identified 63 changes to/from strong activators or inhibitors, whilst only ten were seen in the
GEB052 model. This is due to the fact that feedback loops have been previously identified as
important in the robustness of a network [18]. Although this initial analysis has focussed only
on strong activators or inhibitors, 323 changes to or from activators or inhibitors were identi-
fied across all knockout scenarios, and thus examination of these dependency alterations
would represent a source of future work.
The validation of model LSSA results through cell-based microarray data indicated an aver-
age of 56.60% correct predictions, 41.67% small error and 1.74% large error. The PKT206
interactome model displayed a correct prediction range from 52–71% [18]. The correct predic-
tion range for the GEB052 model was lower (54.17% to 60.42%), less large errors were seen in
the GEB052 model validation; two out of six comparisons yielded no large errors, whilst the
other four led to a large error range of only 2.08% to 4.17%. It is important to note that the
expanded PMH260 interactome displayed less large errors than the original PKT206 model,
and therefore model expansion represents an additional source of future work for the GEB052
model.
Validation of model LSSA results with patient microarray data yielded lower correct
prediction rates (an average of 42%). However, it is still promising that large error predic-
tions comprised the minority of prediction outcomes, suggesting some potential of the
model. Furthermore, working on the assumption that a random model would achieve a
correct prediction rate of 33.3%, then a 42% correct average from thirteen sets of data is
statistically significantly higher (p<0.0001).This lower correct prediction rate could be
attributed to a variety of factors, including the relatively small size of the model, as well as
the complexity of translating findings from a simulation of a small gene regulatory network
to a whole organism level. Additionally, as specified in the introduction, effects of GCs are
very cell-type specific; the GR may differentially modulate genes depending on the type of
tissue. Thus, an additional way to further develop the GR model is through the incorpo-
ration of tissue-specific interactions and the development of cell-specific forms of the
model, although the relevant literature required for this is currently incomplete.
Consistent with previous research [22] the STSFA demonstrated a statistically significantly
higher level of correct prediction rates (80.1% for STSFA compared to 56.6% for LSSA). Curi-
ously, large error predictions for STSFA appeared only in microarray data from B-ALL and
not T-ALL, which indicates that the model may predict T-ALL to a better standard than
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B-ALL. Furthermore, the enhanced predictive power of STSFA (likely due to its semi-quantitative
nature) provided a justification for its use in clinical assessment. By using microarray data from
thirteen leukaemia patients (taken before chemotherapy treatment, and thus analytical outcomes
represent true predictions) Fig 10 was generated. The fact that the model predicted that the
patient who died before risk assessment would have cell death being more inhibited (equating to
death of the cancer cells) is promising, as it provides a potential link between model prediction
and clinical outcome. However, this analysis is admittedly preliminary due to the fact that there
are a small number of patients (13) and one group had only one patient, whilst the other had
twelve. Thus, although promising, further assessment with a larger patient cohort is needed.
Ultimately, the GEB052 model construction, validation, and clinical assessment represent a
proof of principle of the applicability of this approach to glucocorticoid receptor research. The
GEB052 model under Boolean analysis provides good predictive ratios for cell-based microar-
ray data, and application of the semi-quantitative STSFA to the model demonstrated even
higher correct predictive rates. Lastly, the use of the GEB052 model under STSFA analysis has
also shown promise at the clinical level using microarray data from thirteen leukaemia
patients. Key points for future development include model expansion and incorporation of tis-
sue-specific reactions. In addition, it is recognised that there are multiple isoforms of the GR,
each of which can have different effects on downstream nodes, and in fact interactions
between different GR isoforms can be a determinant of its activity [34]. Thus, it may also be
useful to develop models of different GR isoforms to better represent physiological occur-
rences. Regardless of future directions, the GEB052 model represents a promising starting
point and potential clinical tool given its predictive ratios and the correlation of its STSFA out-
put with patient clinical outcomes. Application of individual patient data to the model could
thus be a stepping stone towards personalised therapy.
Methods
Extraction and manual curation of STRING data
STRING (Search Tool for the Retrieval of Interacting Genes/Proteins, v9.1 at the time of cura-
tion) was used as the database of known and predicted protein interactions [24]. Extraction
and filtering of data was performed in a similar manner as described previously [18]. The “pro-
tein.actions.v9.1.txt.gz” file was downloaded from STRING and all high confidence ( 0.7)
interactions for the glucocorticoid receptor were then extracted. TSC22D3 (GILZ, glucocorti-
coid-induced leucine zipper) and EP300 were also included due to their known importance in
GR signalling or similarity to CREBBP respectively.
Manual curation of STRING data was then undertaken via extensive literature searches of
the two putative interacting proteins. STRING includes various interaction modes such as
“activation”, “inhibition” and “binding”. In all cases, manual curation was undertaken to con-
firm STRING records, and also to uncover any functional relationships between the two genes
that were not included in STRING. Manual curation was essential as the nature of the STRING
database (such as being based on text mining) results in the possibility of incorrect interactions
being retained in the database. It has previously been shown that multiple types of errors can
occur such as incorrect gene name recognition [18].
After manual curation of all the interactions with the GR (the “primary layer”), all high-
confidence interactions for the proteins that were shown to interact with GR were extracted.
This list was then filtered to retain interactions only between the proteins which appeared in
the primary layer. Additional curation was then undertaken in order to verify STRING data
(the “second layer”), and thus after this a closed two-layer model was produced. All curations
of predicted interactions were double-curated to improve model reliability.
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Connection to model outputs through the Gene Ontology (GO)
consortium
The GO database [35] was used to provide biological outputs for the model. Following comple-
tion of the second layer, GO terms/annotations were collected for each node of the network,
pooled together and ranked by the most common, and then the most common terms related
to biological outputs were chosen. This lead to several groups of GO terms: cell death; inflam-
mation; immune response; metabolism; development; cell growth and proliferation. For this
first version of the model only cell death and inflammation were chosen as outputs due to
their relevance in glucocorticoid therapy. For all model links to outputs, manual double-cura-
tion was again undertaken to verify interactions.
Cytoscape
Model visualisation was undertaken through the use of Cytoscape, an open-source software
for data visualisation [36]. Curated interaction records were imported into the program and
visualised after adjusting parameters. Application of the STSFA (below) was also conducted in
Cytoscape.
Model analysis through CellNetAnalyzer
CellNetAnalyzer (CNA, v2017.1c) is a MATLAB toolbox which allows for the analysis of gene-
regulatory models based on the topology of the interaction network. Interactions between
nodes of the network are represented through hypergraphs which can allow for interaction
combinations such as OR functions or the use of AND functions, both of which allow for
more accurate representation of true biological reactions (such as several proteins forming a
complex to activate or inhibit a target) [23]. CNA was used to construct Boolean signal flow
networks. At present, the model presented herein does not contain AND reactions; in cases
where interactions converge to the same node the combination follows OR logic by default.
Inhibitory reactions are represented by a NOT modifier. These logics have been described in
detail by Klamt and colleagues [23].
Several types of analysis are available through CNA, such as the generation of an interaction
matrix (which summarises the participation of each node in every reaction), logical steady
state analysis (LSSA) and the generation of dependency matrices. By defining (i.e. ON or OFF)
the state of nodes (particularly input nodes) of the model, LSSA will calculate the steady state
of network nodes downstream of the input based on the interactions within the model. Three
node states are possible under LSSA: 1 (ON), 0 (OFF) or NaN (undetermined). A node may be
assigned NaN if multiple states are possible; this may be caused by input conditions being
insufficient to determine all node states, or through feedback loops leading to multiple steady
states and oscillatory behaviour [18, 37].
The second main approach used in CellNetAnalyzer is the generation of dependency matri-
ces. A dependency matrix provides a visual and numerical representation of the overall rela-
tionships between the nodes of the network, taking into account all of the interactions within
the model (thus allowing indirect functional relationships to be considered). Six different types
of dependencies are possible based on the relationship between nodes in the interaction:
1. A has no effect on B if there are no positive or negative paths from A to B
2. A is a strong activator of B if there are positive paths from A to B, and no negative paths
from A to B. It is also required that there are no negative feedback loops within these posi-
tive paths.
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3. A is a weak activator of B if there are positive paths from A to B, no negative paths from A
to B, and there are negative feedback loops within these positive paths.
4. A is a strong inhibitor of B if there are negative paths from A to B and no positive paths
from A to B. It is also required that there are no negative feedback loops within these nega-
tive paths.
5. A is a weak inhibitor of B if there are negative paths from A to B, no positive paths from A
to B, and there are negative feedback loops within these negative paths.
6. A is ambivalent towards B if there are both positive and negative paths from A to B.
Comparison of the dependency matrices from the full model to a modified (i.e. KO model)
can unveil modified relationships and signalling. Because model KOs simulate in vivo loss-of-
function mutations, these matrix comparisons provide predictions for how cells will behave.
These predictions may then be verified in the laboratory to assess model predictive power and
model accuracy [18, 19].
Comparison of LSSA result scenarios
Comparisons between two sets of LSSA results (such as a GC-sensitive scenario against a GC-
resistant scenario) were also carried out as previously described [18], which allows for the
assessment of node upregulation or downregulation between two scenarios.
In brief, LSSA calculates the state (inactivated (0), undetermined (NaN) or activated (1)) of
nodes within the network following a set of input value(s). For Scenario 1 (i.e. a GC-sensitive
simulation), node i state was defined as S(i)1 which has a value of NaN, 0, or 1. For Scenario 2
(i.e. a GC-resistant simulation), node i state was defined as S(i)2, which may also have a value
of NaN, 0, or 1. Lastly the value Emod was used to define the predicted change in node state
from Scenario 1 to Scenario 2, where 1 means the node is upregulated, -1 means the node is
downregulated and 0 means the node state is unchanged:
Emod ¼   1 if SðiÞ1 ¼ 1 and SðiÞ2 ¼ 0
Emod ¼   1 if SðiÞ1 ¼ 1 and SðiÞ2 ¼ NaN
Emod ¼   1 if SðiÞ1 ¼ NaN and SðiÞ2 ¼ 0
Emod ¼ 0 if SðiÞ1 ¼ 1 and SðiÞ2 ¼ 1
Emod ¼ 0 if SðiÞ1 ¼ 0 and SðiÞ2 ¼ 0
Emod ¼ 0 if SðiÞ1 ¼ NaN and SðiÞ2 ¼ NaN
Emod ¼ 1 if SðiÞ1 ¼ 0 and SðiÞ2 ¼ 1
Emod ¼ 1 if SðiÞ1 ¼ NaN and SðiÞ2 ¼ 1
Emod ¼ 1 if SðiÞ1 ¼ 0 and SðiÞ2 ¼ NaN
Model validation through microarray data
Consistent with previous publications [18, 19] the predictions generated by the GEB052 model
were assessed against microarray data from GC-resistant and GC-sensitive cells. Twelve
microarrays were obtained from the Gene Expression Omnibus (GEO) database, and the fol-
lowing six comparisons were utilised as shown in Table 8.
Differential expression analysis was performed using the dynamic threshold method used
by Tian and colleagues and Hussain and colleagues [18, 19] and the expression change (Eexp)
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value was calculated, where 1 equates to upregulation, 0 to no change, and -1 to downregula-
tion. Using the GC-resistant array as the target scenario, and the GC-sensitive array as the
source scenario, fold changes for all microarray probe IDs were generated between the target
and source scenarios. The Log10 for all fold changes was calculated, and a dynamic threshold
based on the average Log10 fold change + the standard deviation (upper limit) and the average
Log10 fold change–the standard deviation (lower limit).
For each gene present in the model, the median value for all probe IDs relevant to the gene
was calculated for both the source and target scenario, in addition to the fold change of the
median values. For model nodes which represented the combination of multiple genes (i.e. the
AP-1 node which represents FOS and JUN) the median value for all probe IDs for all of its
constituents was used. Log10 values of these fold changes were calculated and compared to the
dynamic threshold; if higher than the upper limit, the gene was determined as upregulated
(Eexp = 1), whilst if the value was lower than the lower limit the gene was determined as down-
regulated (Eexp = -1) and if its value lay between the lower and upper limits then the gene was
determined as unchanged (Eexp = 0).
To evaluate model performance, the absolute value of Emod−Eexp was calculated, which
could take three possible values: 0 (no difference between Emod and Eexp; model prediction was
correct); 1 (small difference between Emod and Eexp; small error prediction) and 2 (large differ-
ence between Emod and Eexp; large error prediction meaning that the model predicted the
opposite of what occurred in cells).
Assessment of model predictions (LSSA) using individual patient data
Table 9 shows the microarray data used for clinical validation of LSSA results.
To compare model LSSA results with clinical data from patients, thirteen microarrays
(detailed above in Table 9) from leukaemia patients (taken following treatment with dexa-
methasone) were obtained from the GEO database [31]. For each individual patient, Log10
RMA values for all probe IDs were calculated and a dynamic threshold based on the average
+/- standard deviation was generated. The median Log10 values for all the probe IDs for genes
within the model were then compared to the threshold: if the value was higher than the upper
limit, the gene was considered as upregulated; if the value was lower than the lower limit, the
gene was considered as downregulated and if the value lay between the lower and upper limits
then the gene was unchanged. These values were then compared to model LSSA results of a
GC-sensitive simulation, where 1 is equivalent to upregulated, 0 to downregulated and NaN to
unchanged.
Table 8. Comparisons for genome-wide model validation.
Comparison GC-Sensitive Array GC-Resistant Array
Comparison
1
T-ALL (C7H2 Cells), 24 Hours Dexamethasone Treatment (GEO
ID GSM60544)
T-ALL (C1 Cells), 24 Hours Dexamethasone Treatment (GEO ID
GSM60562)
Comparison
2
T-ALL (C7H2 Cells), 6 Hours Dexamethasone Treatment (GEO
ID GSM60543)
T-ALL (C1 Cells), 6 Hours Dexamethasone Treatment (GEO ID
GSM60561)
Comparison
3
T-ALL (C7H2 Cells), 6 Hours 0.1% Ethanol Treatment (GEO ID
GSM60542)
T-ALL (C1 Cells), 6 Hours 0.1% Ethanol Treatment (GEO ID
GSM60560)
Comparison
4
B-ALL (PreB 697 Cells), 24 Hours Dexamethasone Treatment
(GEO ID GSM60547)
B-ALL (PreB 697 R4G4 Cells), 24 Hours Dexamethasone Treatment
(GEO ID GSM60586)
Comparison
5
B-ALL (PreB 697 Cells), 6 Hours Dexamethasone Treatment
(GEO ID GSM60546)
B-ALL (PreB 697 R4G4 Cells), 6 Hours Dexamethasone Treatment
(GEO ID GSM60583)
Comparison
6
B-ALL (PreB 697 Cells), 6 Hours 0.1% Ethanol Treatment (GEO
ID GSM60545)
B-ALL (PreB 697 R4G4 Cells), 6 Hours 0.1% Ethanol Treatment (GEO
ID GSM60581)
https://doi.org/10.1371/journal.pcbi.1005825.t008
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Application of the STSFA to GEB052
The STSFA plugin for Cytoscape [21] was used to apply the STSFA to the model. As with pre-
vious studies [19] Log2 RMA values were scaled up by a factor of 100 and superimposed onto
the model using the pathway scoring application. A limitation of the STSFA is that it appar-
ently cannot handle directly ambivalent relationships; that is, if Node A both directly activates
and inhibits Node B, the STSFA cannot accurately handle this. To correct for this, all directly
ambivalent relationships were removed prior to the application of the STSFA. Mathematically,
this is not unreasonable as even if the direct ambivalent interactions were considered, the over-
all regulation would be zero as it would theoretically be positively and negatively affected by
equal amounts. The same twelve microarray datasets listed in Table 8 were used for STSFA
analysis.
STSFA results from the GC-sensitive and GC-resistant arrays were used to generate an Emod
value, whilst the Eexp values for each Comparison were the same as for the cell-based microar-
ray genome-wide model validation. To generate the Emod values, fold changes between the
node scores of the resistant output and sensitive output were generated, followed by the Log10
of the fold changes. From the Log10 fold changes for each node a dynamic threshold based on
the average +/- standard deviation was generated, and nodes were considered as upregulated if
their score was higher than the upper limit, downregulated if their score was lower than the
lower limit, and unchanged if the score lay between the two. These Emod values were compared
to the Eexp values to assess model accuracy in the same way as the cell-based microarray
genome-wide model validation.
Preliminary assessment of GEB052 as a predictive clinical tool (STSFA
using patient data)
To assess the potential of the GEB052 model as a predictive clinical tool, microarray data from
thirteen leukaemia patients (taken before patients were treated) was obtained from the GEO
database, following its deposit after the original study that generated the data [31] (Table 10).
For each patient the STSFA was used to superimpose their microarray data onto the model.
The STSFA assigns node score to every node within the model, in addition to calculating
weights for each of the edges (indicating the “strength” of the regulation). Patients were split
into two groups (alive at risk assessment or dead at risk assessment). The total incoming edge
Table 9. Microarray data used for clinical validation of LSSA data. Data taken from Schmidt and colleagues [31].
Patient Number Gender Age (Years) Clustering Status at Risk Assessment? GEO ID
2 M 8.5 T-ALL Alive GSM51710
13 M 5.9 Not assigned Alive GSM51677
17 F 14.7 Hyperploidy Deceased GSM51680
20 M 5 T-ALL Alive GSM51704
24 M 2.6 Not assigned Alive GSM51674
25 F 10.3 T-ALL Alive GSM51707
31 F 17.2 Hyperploidy Alive GSM51683
32 F 3.7 TEL-AML Alive GSM51686
33 M 2.5 Hyperploidy Alive GSM51689
37 F 15.1 Not assigned Alive GSM51692
38 M 3.2 TEL-AML Alive GSM51695
40 M 17.3 Not assigned Alive GSM51698
43 F 1.6 TEL-AML Alive GSM51701
https://doi.org/10.1371/journal.pcbi.1005825.t009
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weights to cell death (one output of the GEB052 model) was calculated for each patient, and an
average made for each group, in addition to calculating the SEM. This analysis thus correlated
model predictions with clinical outcomes.
P-Value calculation for correct predictions
To assess whether the correct prediction rates of the model were statistically significant, the
WolframAlpha computational knowledge engine (http://www.wolframalpha.com/) was used in
conjunction with the search term “Probability of [X] success in [Y] trials, chance of success is
[Z]”. In these cases [X] equates to the number of correct predictions, [Y] to the total number of
predictions and [Z] to the chance of success (one in three, as there are three possible outcomes).
Determination of incorrect nodes
To determine if any nodes were systematically incorrect across the comparisons shown in
Table 8, the absolute values of Emod−Eexp were totalled for each node and all comparisons. As
previously stated, the absolute value of Emod−Eexp can take three possible values: 0 (correct), 1
(small error) and 2 (large error). A threshold of four (indicating that the node had small errors
in more than 50% of comparisons, or had two large errors) was chosen to determine a node as
incorrect. The incorrect node determination for cell-based microarray validation is shown in
the S1 Text file.
Supporting information
S1 Text. This additional file contains the supplementary tables relevant to this manuscript.
These tables cover information such as the list of interactions within the GEB052 model,
GEB052 model validation and STSFA analysis, and the determination of systematically incor-
rect nodes.
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Table 10. Patient microarray data used for STSFA analysis. Data taken from Schmidt and colleagues [31].
Patient Number Gender Age (Years) Clustering Status at Risk Assessment? GEO ID
2 M 8.5 T-ALL Alive GSM51712
13 M 5.9 Not assigned Alive GSM51679
17 F 14.7 Hyperploidy Deceased GSM51682
20 M 5 T-ALL Alive GSM51706
24 M 2.6 Not assigned Alive GSM51676
25 F 10.3 T-ALL Alive GSM51709
31 F 17.2 Hyperploidy Alive GSM51685
32 F 3.7 TEL-AML Alive GSM51688
33 M 2.5 Hyperploidy Alive GSM51691
37 F 15.1 Not assigned Alive GSM51694
38 M 3.2 TEL-AML Alive GSM51697
40 M 17.3 Not assigned Alive GSM51700
43 F 1.6 TEL-AML Alive GSM51703
https://doi.org/10.1371/journal.pcbi.1005825.t010
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